















The Australian longitudinal Study on Women's Health (Women's Health Australia)

- Self report
- 1996, 2000 and 2003
- Younger women gained 649gm/yr [mid-age 494g/yr; old age lost 162g/yr]
- Young women in rural and remote areas gained significantly more than urban young women

http://www.alswh.org.au











Transition	in Obesity	
	Wave III Non- Obese	Wave III Obese
Wave II Obese	<u>1.6%</u>	9.4%
Wave II Non- Obese	76.3%	<u>12.7%</u>
	 Wave II); 2001/2 (Wave I \m J Clin Nutr 2004	II) – BMI > 95/BMI > 30



Polycystic Ovarian Syndrome (PCOs)



THE UNIVERSITY OF

- The commonest endocrine disorder in women (5-8%) of uncertain aetiology
- <u>Anovulation</u>: amenorrhoea, oligomenorrhoea (< 9 cycles per year), irregular menstrual cycles, dysfunctional uterine bleeding with unopposed oestrogen, endometrial hyperplasia
- <u>Androgen Excess</u>: hirsutism, acne, seborrhoea, male pattern baldness
- Hyperinsulinaemia/Insulin resistance: skin tags, acanthosis nigricans

Prevalence of PCOs

 Population (US) prevalence study (n= 675); NIH criteria; probability algorithm based on previous studies (Yildiz et al JCEM 2008)

BMI class	N (%)	%PCO	
<19	36 (5.3)	8.2	
19- 24.9	282 (41.8)	9.8	
25- 29.9	160 (23.7)	9.9	
30- 34.9	87 (12.9)	5.2	
35- 39.9	57 (8.5)	12.4	
40+	53 (7.8)	11.5	



Fertility and Pregnancy

THE UNIVERSITY OF

Insulin -sensitising drugs (metformin, pioglitazone, rosigltazone and D-chiro-inositol) for women with polycystic ovary syndrome, oligo- amenorrhoea and subfertility

- Tang T. Lord JM. Norman RJ. Yasmin E. Balen AH. Cochrane Database of Systematic Reviews. (1):CD003053, 2010
- There is also evidence that ovulation rates are improved with metformin in women with PCOS for metformin versus placebo (Pooled OR 2.12, 95% CI 1.50 to 3.0) and for metformin and clomiphene versus clomiphene alone (Pooled OR = 3.46, 95% CI 1.97 to 6.07).
- Metformin was also associated with a significantly higher incidence of gastrointestinal disturbance, but no serious adverse effects were reported.
- In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates. However, there is **no** evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene. Therefore, the use of metformin in improving reproductive outcomes in women with PCOS appears to be limited.

	BMI category (kg/m ²)				
	Normal (20.01–25) (n = 6443)	Overweight (25.01-30) (n = 2882)	Obese (30.01–40) (n = 1679)	Morbidly obese (> 40) (n = 248)	Prevalence &
Maternal outcomes				1 Statistic	impact of over-
Hypertensive disorders of pregnancy	1.00	1.74 (1.45–2.15)	3.00 (2.40–3.74)	4.87 (3.27–7.24)	weight and obe
Gestational diabetes	1.00	1.78 (1.25–2.52)	2.95 (2.05–4.25)	7.44 (4.42–12.54)	in an Australiar
Length of stay > 5 days	1.00	1.36 (1.13–1.63)	1.49 (1.21–1.86)	3.18 (2.19–4.61)	Callaway et al
Peripartum outcomes				100000	MJA 2006 (SA)
Caesarean section	1.00	1.50 (1.36–1.66)	2.02 (1.79–2.28)	2.54 (1.94–3.32)	Also Athukora
Neonatal outcomes				2.51 7852	rice ritinationa
Stillborn	1.00	1.16 (0.62–2.17)	1.19 (0.56–2.55)	0.89 (0.12-6.60)	BMC Preg & Ch 2010
Birth defect	1.00	1.26 (0.85, 1.87)	1.58 (1.02–2.46)	3.41 (1.67–6.94)	
Hypoglycaemia	1.00	0.78 (0.36–1.66)	2.57 (1.39–4.78)	7.14 (3.04–16.74)	
Jaundice	1.00	1.02 (0.92–1.12)	0.98 (0.88–1.13)	1.44 (1.09–1.89)	
Prematurity (< 34 weeks' gestation)	1.00	1.22 (0.90–1.64)	1.16 (0.81–1.67)	2.13 (1.13–4.01)	
Prematurity (< 37 weeks' gestation)	1.00	1.07 (0.89–1.28)	0.95 (0.76–1.19)	1.54 (1.00–2.39)	
Admission to intensive care	1.00	0.92	1.25	2.77 (1.81–4.25)	







Iron deficiency in young women

- Nutritional
 Reduced red meat intake
 Vegetarianism
- Vegetarianism
 Menstrual loss
 Menorrhagia with PCOs
- Obesity: (Tussing-Humphreys et al Obesity 2010; 18:1449)
 Iron deficiency common
 High hepcidin state with increased transferrin receptor indicating true iron deficiency
 Primarily a true iron deficit (cf. anaemia of chronic disease where iron stores not released and are high)
 Inflammation with central obesity probably perpetuates the hepcidin increase







Youth & weight loss practice Tsia Ann Int Med2005; Blanck JAMA 2001; Neu-mark-Sztainer Prev Med 1999; Ostbye Mil Med 2003

- Underrepresented in weight loss studies (in NHMRC clinical guidelines mean age study subjects 45years)
 - Underrepresented in clinic attendance at RPAH Metabolism & Obesity Services 18-30 year olds 10% of clinic population 25% only of registered make first visit mean BMI 43
- Female preponderance in commercial weight loss centres
- 25% use non-prescription medications
- Females favour food restriction over exercise
- Interest in weight loss often occurs in the early postpartum period

A 'tailored' approach for Gen Y

- 'Connected' 24 hours
- Not physically unwell
- Used to wide choices
- Managing weight will involve
 - **Expectations**
 - Individuality
 - High mobility
 - Peers & leisure, inc. alcohol
 - **Prolonged dependence** 'adultescence







body comp	position change in puberty		
	Male	<u>Female</u>	
Fat free mass	Doubles	< doubles	
Fat mass	Stable	Increases	
Central fat	5 x	3 x	
Accretion pattern	FFM increases into adulthood	Peri-menarchal gain FM	

